SAILIFE — SAI Life Sciences Balance Sheet
0.000.00%
- IN₹236.25bn
- IN₹236.52bn
- IN₹21.92bn
Annual balance sheet for SAI Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2,159 | 2,049 | 1,847 | 3,723 | 2,618 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5,577 | 5,744 | 6,300 | 8,422 | 3,736 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 9,454 | 9,640 | 9,451 | 15,045 | 14,105 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 11,527 | 11,765 | 12,730 | 16,018 | 20,792 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 21,642 | 21,866 | 22,751 | 31,600 | 36,261 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7,146 | 7,589 | 7,399 | 7,325 | 8,337 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 12,857 | 12,986 | 13,000 | 10,316 | 11,425 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 8,786 | 8,881 | 9,751 | 21,284 | 24,837 |
| Total Liabilities & Shareholders' Equity | 21,642 | 21,866 | 22,751 | 31,600 | 36,261 |
| Total Common Shares Outstanding |